

TABLE OF CONTENT

APPROVAL PAGE	ii
PLAGIARISM FREE STATEMENT	iii
PREFACE	iv
TABLE OF CONTENT	vi
LIST OF TABLES	ix
LIST OF FIGURES	x
LIST OF ABBREVIATION	xi
ABSTRACT	xii
ABSTRAK	xiii
CHAPTER I. INTRODUCTION	1
A. Background	1
B. Problem Formulation	3
C. Research Question	3
D. Study Objective	3
E. Study Authenticity	3
F. Study Benefit	5
CHAPTER II. LITERATURE REVIEW.....	6
A. Literature Review	6
1. Glioma	6
1.1 Definition	6
1.2 Epidemiology	7
1.2.1 Incidence	7
1.2.2 Age	7
1.2.3 Gender and Site	8
1.2.4 Ethnicity and Genetics	8
1.3 Classification	9
1.4 Pathogenesis	10
1.4.1 Diffuse Astrocytoma, WHO Grade II	10
1.4.1.1 TP53	10
1.4.1.2 Platelet-Derived Growth Factor (PDGF)	10
1.4.1.3 IDH1 and IDH2 Mutations in Astrocytoma	10

1.4.1.4 Other DNA Changes	11
1.4.2 Anaplastic Astrocytoma	11
1.4.3 Oligodendroglioma and Anaplastic Oligodendroglioma	11
1.4.4 Secondary GBM	11
1.4.5 Primary GBM	12
1.4.6 Key Functional Pathways in Glioma Pathogenesis	12
1.4.6.1 The p53 Pathway	12
1.4.6.2 The Rb Pathway	12
1.4.7 Growth Factor Receptor Signaling and Angiogenesis	12
1.4.7.1 Receptor Tyrosine Kinase	12
1.4.7.2 Downstream Signaling Pathways	13
1.5 Risk Factors	13
1.5.1 Genetic Risk Factors for Primary Brain Tumors	13
1.5.2 Environmental Risk Factors	14
1.5.2.1 Allergic Conditions and Associated Immunologic Factors	14
1.5.2.2 Ionizing Radiation	15
1.5.2.3 Cellular Telephone Use	15
1.5.2.4 Reproductive and Hormonal Factors	15
1.6 Macroscopic and Microscopic	15
1.7 Clinical Features	17
1.8 Treatments and Prognosis	19
1.8.1 Low Grade Astrocytomas (WHO Grade II)	19
1.8.2 Malignant Astrocytomas (WHO Grade III and IV)	19
2. MGMT	22
2.1 Definition	22
2.2 MGMT Promoter Methylation	23
3. MGMT Methylation Status and Age of Onset	24
B. Theoretical Framework	25
C. Conceptual Framework	25
D. Hypothesis	26
CHAPTER III. METHODOLOGY	27
A. Study Design	27
B. Time and Study Settings	27
C. Study Population and Subject	27
D. Sample Choice	28
E. Sample Size	28
F. Study Variables	29
G. Operational Definition of Variables	29
H. Study Materials and Measurements	31
I. Study Procedures	31
J. Study Molecular Analysis Procedures	32
K. Study Plan	36
L. Statistic Method	36
M. Ethical Clearance	37

CHAPTER IV. RESULTS AND DISCUSSION	38
A. Data Characteristic of Subjects	38
B. qPCR Result of Subjects' MGMT Promoter	39
C. Statistical Analysis Results.....	40
D. Study Limitation	47
CHAPTER V. CONCLUSION AND SUGGESTION	48
A. Conclusion	48
B. Suggestion	48
REFERENCES	49
APPENDICES	55

LIST OF TABLES

Table 1. Research Authenticity	3
Table 2. Risk Factors of Glioma	14
Table 3. Study Plan	36
Table 4. Method of Statistics	37
Table 5. Glioma Patients' Data	39
Table 6. MGMT Methylation Status	40
Table 7. Statistical analysis for association of MGMT promoter methylation status with age of onset	41
Table 8. Statistical analysis for association of sex with age of onset	42
Table 9. Statistical analysis for association of histopathology types with age of onset	44
Table 10. Statistical Analysis for association of grades of tumor with age of onset	45
Table 11. Linear Regression Result	47

LIST OF FIGURES

Figure 1. Classification of Glioma according to WHO.....	10
Figure 2. Pathogenesis of Glioma	13
Figure 3. Algorithm for diagnosis and treatment of glioma	18
Figure 4. Theoretical Framework	25
Figure 5. Conceptual Framework	26
Figure 6. DNA Amplification of unmethylated sample 10	40
Figure 7. DNA Amplification of methylated sample 5.....	40

LIST OF ABBREVIATIONS

Abbreviations	Details
5-ALA	5-Aminolevulinic acid
BBB	Blood Brain Barrier
CNS	Central Nervous System
COL2A1	Collagen 2A1
CRF	Case Report Form
CSF	Cerebrospinal Fluid
DNA	Deoxyribonucleic Acid
EGFR	Epidermal Growth Factor Receptor
Gy	Gray
IDH	Isocitrate Dehydrogenase
MGMT	O ⁶ -Methylguanine DNA Methyltransferase
OS	Overall Survival
PDGF	Platelet-Derived Growth Factor
PFS	Progression Free Survival
PNS	Peripheral Nervous System
qPCR	Quantitative Polymerase Chain Reaction
TP53	Tumor Protein P53
WHO	World Health Organization
XRT	Radiation Therapy